A phase III randomized, double blind, placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative AI treated, locally advanced or metastatic breast cancer who progressed on or after mTOR inhibitor based treatment
To find out if BKM120 plus fulvestrant prolongs survival compared to placebo plus fulvestrant
1. Evidence of locally advanced or metastatic disease.
2. HER2- and HR+ breast cancer
3. Previously treated with aromatase inhibitors (AIs)
4. Evidence of progressive disease after mTOR and endocrine therapy
5. Other criteria may apply
18 - 100
Healthy Volunteers Needed
Duration of Participation
Until disease progression, unacceptable side effects, death, or discontinuation for any other reasons.
Knight Clinical Trials Information Line